article thumbnail

Novaliq’s dry eye disease therapy receives US FDA approval

Pharmaceutical Technology

Novaliq medical science and regulatory affairs vice-president Sonja Krösser stated: “We are proud that the FDA approved VEVYE. The safety and efficacy of VEVYE were assessed in a total of 1,369 patients with dry eye disease, of which 738 received VEVYE. “It

article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

These efficacy results, combined with the safety profile that allows patients to complete their treatment regimen, are extremely encouraging. Can you share some highlights from the data presented at ASH 2023? The IND for the combination was cleared in May 2023 and we have now treated patients in the first two cohorts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

It’s Time We Got the Most Out of Medical Affairs Data

PM360

Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Historically, the industry has left MSL-HCP interactions to exist on their own, focusing on objective metrics and key performance indicators (KPIs) to inform Medical Affairs impact. October 2023. EPG Health.

Medical 52
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4].

article thumbnail

What Tech Trends Do Life Sciences Marketers Need to Know About?

PM360

Casey Cronin Life sciences marketers have a unique opportunity to connect with target audiences on an individual level and foster brand safety through AI advancement. Will Big Tech’s moves within healthcare force the industry to change how it operates? Here are the best responses.

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

Moreover, due to the different nature of healthy and cancerous tissue, alpha radiation produced by Alpha DaRT sources diffuses about a millimeter into healthy tissue while penetrating at a diameter up to about five millimeters into tumors, providing an automatic safety mechanism. More info can be found at the Biomed Israel website.